Literature DB >> 10543748

Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide.

V Prasad1, S Hashim, A Mukhopadhyay, S K Basu, R P Roy.   

Abstract

The poor membrane permeability of oligonucleotides is one of the major problems of antisense technology. Here we report the construction of designer oligonucleotides for targeted delivery to macrophages. The oligonucleotides tethered to a 10-mer poly(G) sequence at their 3' ends were recognized by scavenger receptors on macrophages and were taken up about 8- to 10-fold as efficiently as those oligonucleotides that either lacked a poly(G) tail or that contained a 10-mer poly(C) tail instead of the poly(G) tail. The enhanced uptake of poly(G) constructs was inhibited in the presence of poly(G) and other known ligands of the scavenger receptor. The bioefficacy of poly(G)-mediated targeting of antisense oligonucleotides (ANS) was demonstrated by using vesicular stomatitis virus (VSV) as a model system. The ability of ANS directed against the translation initiation site of N protein mRNA of VSV to inhibit virus replication was assessed. The ANS with the 10-mer poly(G) sequences (ANS-G) brought about significant inhibition of VSV replication in J774E cells (a murine monocyte/macrophage cell line) and Chinese hamster ovary (CHO) cell transfectants expressing scavenger receptors. The ANS lacking a 10-mer poly(G) stretch were ineffective. The inhibition of VSV replication due to ANS-G was completely abrogated in the presence of 10-mer poly(G), indicating that the antisense effect of the ANS-G molecule was a consequence of scavenger receptor-mediated enhanced uptake. Importantly, antisense molecules linked exclusively by natural phosphodiester bonds were as bioeffective as those synthesized with a mixed backbone of phosphodiester and phosphorothioate. Taken together, these results suggest that macrophage-directed designer ANS against infective agents may simply be obtained by adding a short stretch of guanylic acid sequence to the desired specific ANS during solid-phase synthesis. This nucleic acid-based strategy, which utilizes homogeneous preparation of ANS, may find applications in directed manipulation of macrophage metabolism for a variety of purposes as well as in therapy of a broad spectrum of macrophage-related disorders amenable to the antisense approach.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543748      PMCID: PMC89544     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

1.  [14] Maleylation of amino groups.

Authors:  P J Butler; B S Hartley
Journal:  Methods Enzymol       Date:  1972       Impact factor: 1.600

Review 2.  Phosphorothioate antisense oligodeoxynucleotides: questions of specificity.

Authors:  C A Stein
Journal:  Trends Biotechnol       Date:  1996-05       Impact factor: 19.536

3.  Inhibition of vesicular stomatitis virus in cells constitutively expressing an antisense RNA targeted against the virus RNA polymerase gene.

Authors:  A M Takacs; A K Banerjee
Journal:  J Gen Virol       Date:  1997-01       Impact factor: 3.891

4.  Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors.

Authors:  E A Biessen; H Vietsch; J Kuiper; M K Bijsterbosch; T J Berkel
Journal:  Mol Pharmacol       Date:  1998-02       Impact factor: 4.436

5.  Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.

Authors:  J L Goldstein; Y K Ho; S K Basu; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

6.  Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide.

Authors:  L Benimetskaya; M Berton; A Kolbanovsky; S Benimetsky; C A Stein
Journal:  Nucleic Acids Res       Date:  1997-07-01       Impact factor: 16.971

7.  Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells.

Authors:  J L Tonkinson; C A Stein
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971

8.  Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite.

Authors:  G Chaudhuri
Journal:  Biochem Pharmacol       Date:  1997-02-07       Impact factor: 5.858

9.  Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein.

Authors:  L Benimetskaya; J D Loike; Z Khaled; G Loike; S C Silverstein; L Cao; J el Khoury; T Q Cai; C A Stein
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

10.  Enhanced cellular uptake of oligonucleotides by EGF receptor-mediated endocytosis in A549 cells.

Authors:  D Deshpande; D Toledo-Velasquez; D Thakkar; W Liang; Y Rojanasakul
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

View more
  6 in total

Review 1.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

2.  Inhibition of HIV-1 gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-1 TAT/Rev RNA.

Authors:  H Unwalla; A C Banerjea
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

3.  Type-A CpG oligonucleotides activate exclusively porcine natural interferon-producing cells to secrete interferon-alpha, tumour necrosis factor-alpha and interleukin-12.

Authors:  Laurence Guzylack-Piriou; Carole Balmelli; Kenneth C McCullough; Artur Summerfield
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

Review 4.  Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?

Authors:  Elizabeth R Rayburn; Ruiwen Zhang
Journal:  Drug Discov Today       Date:  2008-05-03       Impact factor: 7.851

5.  TARGETING OF MACROPHAGE FOAM CELLS IN ATHEROSCLEROTIC PLAQUE USING OLIGONUCLEOTIDE-FUNCTIONALIZED NANOPARTICLES.

Authors:  Gaurav Sharma; Zhi-Gang She; David T Valenta; William B Stallcup; Jeffrey W Smith
Journal:  Nano Life       Date:  2010-09

Review 6.  Involvement of long noncoding RNAs in diseases affecting the central nervous system.

Authors:  Chiara Pastori; Claes Wahlestedt
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.